ArticleBiomedical engineering letters2025
Innovative breast cancer detection using a segmentation-guided ensemble classification framework.
Article in Biomedical engineering letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HER2 Score-Aware Virtual Immunohistochemistry via Non-Contrastive Multi-Task Translation.Diagnostics (Basel, Switzerland) · 2026Article
- Efficient sparse-view medical image classification for low radiation and rapid COVID-19 diagnosis.Biomedical engineering letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains a significant global health issue, necessitating innovative methodologies to improve early detection and diagnosis. Despite the existence of intelligent deep learning models, their efficacy is often limited due to the oversight of small-sized masses, leading to false positive and false negative outcomes. This research introduces a novel segmentation-guided classification model developed to increase BC detection accuracy. The designed model unfolds in two critical phases, each contributing to a comprehensive BC diagnostic pipeline. In Phase I, the Attention U-Net model is utilized for BC segmentation. The encoder extracts hierarchical features, while the decoder, supported by attention mechanisms, refines the segmentation, focusing on suspicious regions. In Phase II, a novel ensemble approach is introduced for BC classification, involving various feature extraction methods, base classifiers, and a meta-classifier. An ensemble of model classifiers-including support vector machine, decision trees, k-nearest neighbor and artificial neural network- captures diverse patterns within these features. The Random Forest meta-classifier amalgamates their outputs, leveraging their collective strengths. The proposed integrated model accurately identifies different breast tumor classes, including malignant, benign, and normal. The precise region-of-interest analysis from segmentation phase significantly boosted classification performance of ensemble meta-classifier. The model accomplished an overall accuracy rate of 99.57% with high segmentation performance of 95% f1-score, illustrating its high discriminative power in detecting malignant, benign, and normal cases within the ultrasound image dataset. This research contributes to reducing breast tumor morbidity and mortality by facilitating early detection and timely intervention, ultimately supporting better patient outcomes. Supplementary Information: The online version contains supplementary material available at 10.1007/s13534-024-00435-7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.